Teva Pharmaceutical Industries (WBO:TEVA) Debt-to-Equity : 3.18 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Teva Pharmaceutical Industries Debt-to-Equity?

Teva Pharmaceutical Industries's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €2,325 Mil. Teva Pharmaceutical Industries's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €15,042 Mil. Teva Pharmaceutical Industries's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €5,465 Mil. Teva Pharmaceutical Industries's debt to equity for the quarter that ended in Sep. 2024 was 3.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Teva Pharmaceutical Industries's Debt-to-Equity or its related term are showing as below:

WBO:TEVA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.33 Med: 1.97 Max: 3.18
Current: 3.18

During the past 13 years, the highest Debt-to-Equity Ratio of Teva Pharmaceutical Industries was 3.18. The lowest was 0.33. And the median was 1.97.

WBO:TEVA's Debt-to-Equity is ranked worse than
95.88% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs WBO:TEVA: 3.18

Teva Pharmaceutical Industries Debt-to-Equity Historical Data

The historical data trend for Teva Pharmaceutical Industries's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Debt-to-Equity Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.96

2.63

2.28

2.76

2.69

Teva Pharmaceutical Industries Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															2.93	2.69	2.74	2.98	3.18

Competitive Comparison of Teva Pharmaceutical Industries's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Debt-to-Equity falls into.

Teva Pharmaceutical Industries Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Teva Pharmaceutical Industries's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1533.224	+	16947.077)	/	6883.002
	=	2.68

Teva Pharmaceutical Industries's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2324.58	+	15042.195)	/	5464.565
	=	3.18

Teva Pharmaceutical Industries (WBO:TEVA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Teva Pharmaceutical Industries Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (WBO:TEVA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEV:Bulgaria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.